Respiratory Medicine
Volume 100, Issue 9 , Pages 1651-1656 , September 2006

Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma

Received 30 October 2005 ,Accepted 12 December 2005.

References 

  1. Barnes PJ. Therapeutic strategies for allergic diseases. Nature. 1999;402(6720 Suppl.):B31–B38
  2. O’Bryne PM, Postma DS. The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Asthma Research Group. Am J Respir Crit Care Med. 1999;159(5 Pt2):S41–S63
  3. Humbert M. Ciclesonide: a novel inhaled corticosteroid. Expert Opin Invest Drugs. 2004;13(10):1349–1360
  4. Alving K, Weitzberg E, Lundberg M. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J. 1993;6:1368–1372
  5. Lim S, Jatakanon A, John M, et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med. 1999;159:22–30
  6. Lim S, Jatakanon A, Meah S, et al. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax. 2000;55:184–188
  7. Kharitonov S, Donnely LE, Corradi M, et al. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax. 2002;57:889–896
  8. Silkoff PE, McClean P, Spino M, et al. Dose–response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest. 2001;119:1322–1328
  9. Smith AD, Cowan JO, Filsel S, et al. Diagnosing asthma. Comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med. 2004;169:473–478
  10. Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/WHO Report 2002, publication 02-3569.
  11. American Thoracic Society/American Lung Association Recommendations for On-line Measurement of Exhaled Nitric Oxide in Adults and the Recommendations for On-line. Offline and nasal expired nitric oxide measurements in children. Am J Respir Crit Care Med. 1999;160:2104–2117
  12. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144:1202–1218
  13. Meyts I, Proesmans M, De Boeck K. Exhaled nitric oxide corresponds with office evaluation of asthma control. Pediatr Pulmunol. 2003;36:283–289
  14. Leung SY, Eynott P, Nath P, Chung KF. Effects of ciclesonide and fluticasone propionate on allergen induced airway inflammation and remodeling features. J Allergy Clin Immunol. 2005;115(5):989–996
  15. Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med. 2005;99(10):1275–1285
  16. Ukena D, Biberger C, von Behren V, et al. Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study. Eur Respir J. 2003;22(Suppl. 45):411
  17. Buhl R, Vinkler I, Magyar P, et al. Once daily ciclesonide is as effective as fluticasone propionate given twice daily in treating patients with asthma. Am J Respir Crit Care Med. 2004;169:A91
  18. Kanniess F, Richter K, Bohme S, Jorres RA, Magnussen H. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther. 2001;14(2):141–147
  19. Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest. 2005;127(3):851–860
  20. Lee DK, Haggart K, Currie GP, et al. Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol. 2004;58(1):26–33
  21. Thompson PJ. Drug delivery to the small airways. Am J Respir Crit Care Med. 1998;157:199–202
  22. Rohatagi S, Derendorf H, Zech K, et al. PK/PD of inhaled corticosteroids: the risk/benefit of inhaled ciclesonide. J Allergy Clin Immunol. 2003;111:A598
  23. Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;91:326–334
  24. Nave R, Sattele N, Mayer W. Formation of fatty acid conjugates of ciclesonide-active principle in the rat lung after 4-week inhalation of ciclesonide. Am J Respir Crit Care Med. 2003;167:A1509

PII: S0954-6111(05)00527-5

doi: 10.1016/j.rmed.2005.12.004

Respiratory Medicine
Volume 100, Issue 9 , Pages 1651-1656 , September 2006

Article Tools

* Image Usage & Resolution